nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—MTOR—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.0317	0.0519	CbGpPWpGaD
Pimecrolimus—Skin infection—Lisinopril—dilated cardiomyopathy	0.0232	0.0597	CcSEcCtD
Pimecrolimus—Application site pain—Furosemide—dilated cardiomyopathy	0.0212	0.0546	CcSEcCtD
Pimecrolimus—MTOR—S6K1-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.0197	0.0323	CbGpPWpGaD
Pimecrolimus—MTOR—mTORC1-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.0168	0.0275	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NPPB—dilated cardiomyopathy	0.0132	0.0217	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—FASLG—dilated cardiomyopathy	0.0131	0.0215	CbGpPWpGaD
Pimecrolimus—FKBP1A—TOR Signaling—RPS6KB1—dilated cardiomyopathy	0.0116	0.0189	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.0113	0.0185	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.011	0.0179	CbGpPWpGaD
Pimecrolimus—FKBP1A—TOR Signaling—RAC1—dilated cardiomyopathy	0.0105	0.0171	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.0101	0.0166	CbGpPWpGaD
Pimecrolimus—Throat sore—Lisinopril—dilated cardiomyopathy	0.00972	0.025	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.00963	0.0248	CcSEcCtD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—CXCR3—dilated cardiomyopathy	0.00924	0.0151	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.009	0.0147	CbGpPWpGaD
Pimecrolimus—Otitis media—Lisinopril—dilated cardiomyopathy	0.00899	0.0231	CcSEcCtD
Pimecrolimus—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.00864	0.0222	CcSEcCtD
Pimecrolimus—FKBP1A—TGF-beta receptor signaling—RPS6KB1—dilated cardiomyopathy	0.00862	0.0141	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—NPPA—dilated cardiomyopathy	0.0086	0.0141	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00819	0.0134	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signalling—RPS6KB1—dilated cardiomyopathy	0.00819	0.0134	CbGpPWpGaD
Pimecrolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—dilated cardiomyopathy	0.0081	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—PKB-mediated events—RPS6KB1—dilated cardiomyopathy	0.00796	0.013	CbGpPWpGaD
Pimecrolimus—Viral infection—Lisinopril—dilated cardiomyopathy	0.00775	0.0199	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.0077	0.0198	CcSEcCtD
Pimecrolimus—Swelling—Furosemide—dilated cardiomyopathy	0.00768	0.0198	CcSEcCtD
Pimecrolimus—MTOR—VEGFR2 mediated vascular permeability—RAC1—dilated cardiomyopathy	0.00719	0.0118	CbGpPWpGaD
Pimecrolimus—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00718	0.0185	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00714	0.0117	CbGpPWpGaD
Pimecrolimus—Wheezing—Lisinopril—dilated cardiomyopathy	0.0068	0.0175	CcSEcCtD
Pimecrolimus—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.0068	0.0175	CcSEcCtD
Pimecrolimus—MTOR—TOR Signaling—RPS6KB1—dilated cardiomyopathy	0.00651	0.0106	CbGpPWpGaD
Pimecrolimus—MTOR—CD28 co-stimulation—RAC1—dilated cardiomyopathy	0.00646	0.0106	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—RPS6KB1—dilated cardiomyopathy	0.00637	0.0104	CbGpPWpGaD
Pimecrolimus—MTOR—Alpha 6 Beta 4 signaling pathway—RAC1—dilated cardiomyopathy	0.0063	0.0103	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NPPA—dilated cardiomyopathy	0.00613	0.01	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00612	0.0157	CcSEcCtD
Pimecrolimus—MTOR—TOR Signaling—RAC1—dilated cardiomyopathy	0.00588	0.00962	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—RAC1—dilated cardiomyopathy	0.00575	0.00941	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—GJA1—dilated cardiomyopathy	0.00575	0.0094	CbGpPWpGaD
Pimecrolimus—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00574	0.0148	CcSEcCtD
Pimecrolimus—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.00558	0.0144	CcSEcCtD
Pimecrolimus—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00534	0.0137	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.00533	0.00873	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.00531	0.00868	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—RAC1—dilated cardiomyopathy	0.0053	0.00867	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00528	0.0136	CcSEcCtD
Pimecrolimus—Face oedema—Lisinopril—dilated cardiomyopathy	0.00491	0.0126	CcSEcCtD
Pimecrolimus—MTOR—FSH signaling pathway—RAF1—dilated cardiomyopathy	0.00491	0.00803	CbGpPWpGaD
Pimecrolimus—Urticaria—Spironolactone—dilated cardiomyopathy	0.00486	0.0125	CcSEcCtD
Pimecrolimus—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00484	0.0124	CcSEcCtD
Pimecrolimus—MTOR—Interferon type I signaling pathways—RPS6KB1—dilated cardiomyopathy	0.0047	0.0077	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.0047	0.0077	CbGpPWpGaD
Pimecrolimus—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00459	0.0118	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00455	0.0117	CcSEcCtD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—RAF1—dilated cardiomyopathy	0.00451	0.00738	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00451	0.0116	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.0044	0.0072	CbGpPWpGaD
Pimecrolimus—Asthma—Lisinopril—dilated cardiomyopathy	0.00439	0.0113	CcSEcCtD
Pimecrolimus—Influenza—Lisinopril—dilated cardiomyopathy	0.00439	0.0113	CcSEcCtD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—RAC1—dilated cardiomyopathy	0.00438	0.00717	CbGpPWpGaD
Pimecrolimus—Eye disorder—Furosemide—dilated cardiomyopathy	0.00438	0.0113	CcSEcCtD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL10—dilated cardiomyopathy	0.00433	0.00708	CbGpPWpGaD
Pimecrolimus—Pruritus—Spironolactone—dilated cardiomyopathy	0.00433	0.0111	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.00432	0.00707	CbGpPWpGaD
Pimecrolimus—MTOR—Interferon type I signaling pathways—RAC1—dilated cardiomyopathy	0.00425	0.00695	CbGpPWpGaD
Pimecrolimus—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00423	0.0109	CcSEcCtD
Pimecrolimus—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00423	0.0109	CcSEcCtD
Pimecrolimus—MTOR—IL4-mediated signaling events—RPS6KB1—dilated cardiomyopathy	0.00421	0.00689	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.00419	0.00685	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00419	0.00685	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00419	0.0108	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—FASLG—dilated cardiomyopathy	0.00413	0.00676	CbGpPWpGaD
Pimecrolimus—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00408	0.0105	CcSEcCtD
Pimecrolimus—Malnutrition—Furosemide—dilated cardiomyopathy	0.00408	0.0105	CcSEcCtD
Pimecrolimus—Erythema—Furosemide—dilated cardiomyopathy	0.00408	0.0105	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.00404	0.00662	CbGpPWpGaD
Pimecrolimus—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00401	0.0103	CcSEcCtD
Pimecrolimus—MTOR—TSH signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00401	0.00655	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00401	0.00655	CbGpPWpGaD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—RAF1—dilated cardiomyopathy	0.00399	0.00652	CbGpPWpGaD
Pimecrolimus—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00394	0.0101	CcSEcCtD
Pimecrolimus—MTOR—PI3K Cascade—RPS6KB1—dilated cardiomyopathy	0.00391	0.0064	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—RPS6KB1—dilated cardiomyopathy	0.00391	0.0064	CbGpPWpGaD
Pimecrolimus—Vomiting—Spironolactone—dilated cardiomyopathy	0.00389	0.01	CcSEcCtD
Pimecrolimus—MTOR—AMPK Signaling—RPS6KB1—dilated cardiomyopathy	0.00387	0.00633	CbGpPWpGaD
Pimecrolimus—Rash—Spironolactone—dilated cardiomyopathy	0.00386	0.00993	CcSEcCtD
Pimecrolimus—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00386	0.00992	CcSEcCtD
Pimecrolimus—Headache—Spironolactone—dilated cardiomyopathy	0.00383	0.00986	CcSEcCtD
Pimecrolimus—MTOR—CDC42 signaling events—RPS6KB1—dilated cardiomyopathy	0.00382	0.00625	CbGpPWpGaD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—dilated cardiomyopathy	0.00378	0.00618	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—RAF1—dilated cardiomyopathy	0.00373	0.00611	CbGpPWpGaD
Pimecrolimus—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00369	0.00951	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—PSEN2—dilated cardiomyopathy	0.00369	0.00604	CbGpPWpGaD
Pimecrolimus—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00368	0.00945	CcSEcCtD
Pimecrolimus—Nausea—Spironolactone—dilated cardiomyopathy	0.00364	0.00935	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00362	0.00592	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—RAC1—dilated cardiomyopathy	0.00353	0.00578	CbGpPWpGaD
Pimecrolimus—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00353	0.00907	CcSEcCtD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—RAF1—dilated cardiomyopathy	0.00351	0.00575	CbGpPWpGaD
Pimecrolimus—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00349	0.00898	CcSEcCtD
Pimecrolimus—MTOR—CDC42 signaling events—RAC1—dilated cardiomyopathy	0.00345	0.00565	CbGpPWpGaD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00345	0.00887	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00333	0.00857	CcSEcCtD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—dilated cardiomyopathy	0.00327	0.00535	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—RPS6KB1—dilated cardiomyopathy	0.00327	0.00535	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—RAC1—dilated cardiomyopathy	0.00327	0.00535	CbGpPWpGaD
Pimecrolimus—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00327	0.0084	CcSEcCtD
Pimecrolimus—Flushing—Lisinopril—dilated cardiomyopathy	0.00326	0.0084	CcSEcCtD
Pimecrolimus—Skin disorder—Furosemide—dilated cardiomyopathy	0.00323	0.00832	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events—RPS6KB1—dilated cardiomyopathy	0.00318	0.00521	CbGpPWpGaD
Pimecrolimus—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00317	0.00815	CcSEcCtD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—RPS6KB1—dilated cardiomyopathy	0.00315	0.00516	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAC1—dilated cardiomyopathy	0.0031	0.00508	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—dilated cardiomyopathy	0.00309	0.00506	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—RPS6KB1—dilated cardiomyopathy	0.00307	0.00503	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—RPS6KB1—dilated cardiomyopathy	0.00307	0.00503	CbGpPWpGaD
Pimecrolimus—Erythema—Lisinopril—dilated cardiomyopathy	0.00306	0.00788	CcSEcCtD
Pimecrolimus—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00306	0.00788	CcSEcCtD
Pimecrolimus—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00299	0.00769	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—RAC1—dilated cardiomyopathy	0.00298	0.00488	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.00298	0.00488	CbGpPWpGaD
Pimecrolimus—Back pain—Lisinopril—dilated cardiomyopathy	0.00296	0.00762	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00291	0.00476	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00287	0.0074	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.00285	0.00467	CbGpPWpGaD
Pimecrolimus—Constipation—Furosemide—dilated cardiomyopathy	0.00285	0.00733	CcSEcCtD
Pimecrolimus—Pain—Furosemide—dilated cardiomyopathy	0.00285	0.00733	CcSEcCtD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00281	0.00459	CbGpPWpGaD
Pimecrolimus—Angioedema—Lisinopril—dilated cardiomyopathy	0.0028	0.0072	CcSEcCtD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.00278	0.00454	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00275	0.0045	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00272	0.007	CcSEcCtD
Pimecrolimus—Cough—Lisinopril—dilated cardiomyopathy	0.00267	0.00687	CcSEcCtD
Pimecrolimus—Urticaria—Furosemide—dilated cardiomyopathy	0.00265	0.00681	CcSEcCtD
Pimecrolimus—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00263	0.00677	CcSEcCtD
Pimecrolimus—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00263	0.00677	CcSEcCtD
Pimecrolimus—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00261	0.0067	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00259	0.00666	CcSEcCtD
Pimecrolimus—MTOR—Signaling by Insulin receptor—RPS6KB1—dilated cardiomyopathy	0.00255	0.00417	CbGpPWpGaD
Pimecrolimus—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.0025	0.00643	CcSEcCtD
Pimecrolimus—Oedema—Lisinopril—dilated cardiomyopathy	0.0025	0.00643	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—RAC1—dilated cardiomyopathy	0.0025	0.00408	CbGpPWpGaD
Pimecrolimus—Infection—Lisinopril—dilated cardiomyopathy	0.00248	0.00639	CcSEcCtD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—RAC1—dilated cardiomyopathy	0.00246	0.00402	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00245	0.00631	CcSEcCtD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—RAF1—dilated cardiomyopathy	0.00243	0.00398	CbGpPWpGaD
Pimecrolimus—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00243	0.00624	CcSEcCtD
Pimecrolimus—MTOR—mTOR signaling pathway—RAF1—dilated cardiomyopathy	0.0024	0.00393	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—RAF1—dilated cardiomyopathy	0.0024	0.00393	CbGpPWpGaD
Pimecrolimus—Pruritus—Furosemide—dilated cardiomyopathy	0.00236	0.00606	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—RAC1—dilated cardiomyopathy	0.00232	0.0038	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.00232	0.00379	CbGpPWpGaD
Pimecrolimus—MTOR—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.00229	0.00375	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00228	0.00586	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00228	0.00586	CcSEcCtD
Pimecrolimus—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00224	0.00577	CcSEcCtD
Pimecrolimus—MTOR—Signaling by NGF—PSEN2—dilated cardiomyopathy	0.00223	0.00364	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00223	0.00573	CcSEcCtD
Pimecrolimus—MTOR—Leptin signaling pathway—RAF1—dilated cardiomyopathy	0.00217	0.00355	CbGpPWpGaD
Pimecrolimus—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00216	0.00555	CcSEcCtD
Pimecrolimus—MTOR—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00215	0.00351	CbGpPWpGaD
Pimecrolimus—Constipation—Lisinopril—dilated cardiomyopathy	0.00214	0.0055	CcSEcCtD
Pimecrolimus—Pain—Lisinopril—dilated cardiomyopathy	0.00214	0.0055	CcSEcCtD
Pimecrolimus—Vomiting—Furosemide—dilated cardiomyopathy	0.00212	0.00545	CcSEcCtD
Pimecrolimus—Rash—Furosemide—dilated cardiomyopathy	0.0021	0.0054	CcSEcCtD
Pimecrolimus—Dermatitis—Furosemide—dilated cardiomyopathy	0.0021	0.0054	CcSEcCtD
Pimecrolimus—Headache—Furosemide—dilated cardiomyopathy	0.00209	0.00537	CcSEcCtD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—dilated cardiomyopathy	0.00206	0.00337	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00204	0.00526	CcSEcCtD
Pimecrolimus—Urticaria—Lisinopril—dilated cardiomyopathy	0.00198	0.00511	CcSEcCtD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.00198	0.00324	CbGpPWpGaD
Pimecrolimus—Nausea—Furosemide—dilated cardiomyopathy	0.00198	0.00509	CcSEcCtD
Pimecrolimus—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00197	0.00508	CcSEcCtD
Pimecrolimus—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00197	0.00508	CcSEcCtD
Pimecrolimus—MTOR—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.00197	0.00323	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—RAC1—dilated cardiomyopathy	0.00197	0.00323	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—RAF1—dilated cardiomyopathy	0.00196	0.00321	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00195	0.0032	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00194	0.00317	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.00193	0.00316	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—RAF1—dilated cardiomyopathy	0.00191	0.00312	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—RAF1—dilated cardiomyopathy	0.00189	0.00309	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00187	0.00305	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00184	0.00474	CcSEcCtD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—RAF1—dilated cardiomyopathy	0.00184	0.00301	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—RAF1—dilated cardiomyopathy	0.00184	0.00301	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.00184	0.00301	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.00182	0.00298	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—dilated cardiomyopathy	0.00181	0.00297	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—RAC1—dilated cardiomyopathy	0.00178	0.00292	CbGpPWpGaD
Pimecrolimus—Pruritus—Lisinopril—dilated cardiomyopathy	0.00177	0.00455	CcSEcCtD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.00177	0.00289	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.00175	0.00286	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—RAC1—dilated cardiomyopathy	0.00175	0.00286	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00171	0.0044	CcSEcCtD
Pimecrolimus—MTOR—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.00166	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.00166	0.00271	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—RAC1—dilated cardiomyopathy	0.00164	0.00269	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.00164	0.00269	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.00163	0.00267	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.00161	0.00263	CbGpPWpGaD
Pimecrolimus—Vomiting—Lisinopril—dilated cardiomyopathy	0.00159	0.00409	CcSEcCtD
Pimecrolimus—Rash—Lisinopril—dilated cardiomyopathy	0.00158	0.00405	CcSEcCtD
Pimecrolimus—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00157	0.00405	CcSEcCtD
Pimecrolimus—Headache—Lisinopril—dilated cardiomyopathy	0.00157	0.00403	CcSEcCtD
Pimecrolimus—MTOR—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.00154	0.00252	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—RAF1—dilated cardiomyopathy	0.00153	0.0025	CbGpPWpGaD
Pimecrolimus—Nausea—Lisinopril—dilated cardiomyopathy	0.00148	0.00382	CcSEcCtD
Pimecrolimus—MTOR—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.00136	0.00223	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—dilated cardiomyopathy	0.00133	0.00218	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—RAF1—dilated cardiomyopathy	0.00131	0.00214	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—GPX1—dilated cardiomyopathy	0.0013	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—dilated cardiomyopathy	0.00129	0.00211	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.00129	0.0021	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—NPPA—dilated cardiomyopathy	0.00125	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—RAF1—dilated cardiomyopathy	0.00125	0.00205	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00125	0.00205	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—RAF1—dilated cardiomyopathy	0.00123	0.00201	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—PSEN2—dilated cardiomyopathy	0.00121	0.00199	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—EGFR—dilated cardiomyopathy	0.0012	0.00196	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.00119	0.00195	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—RAF1—dilated cardiomyopathy	0.00118	0.00193	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—RAF1—dilated cardiomyopathy	0.00118	0.00192	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—EGFR—dilated cardiomyopathy	0.00117	0.00192	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.00117	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—RAF1—dilated cardiomyopathy	0.00117	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—RAF1—dilated cardiomyopathy	0.00116	0.00191	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—EGFR—dilated cardiomyopathy	0.00116	0.0019	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—RAF1—dilated cardiomyopathy	0.00116	0.0019	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—dilated cardiomyopathy	0.00114	0.00186	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.00114	0.00186	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—RAC1—dilated cardiomyopathy	0.00112	0.00183	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—RAF1—dilated cardiomyopathy	0.00109	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.00109	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—RAF1—dilated cardiomyopathy	0.00109	0.00178	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—RAF1—dilated cardiomyopathy	0.00108	0.00177	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—RAF1—dilated cardiomyopathy	0.00107	0.00175	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—RAF1—dilated cardiomyopathy	0.00107	0.00174	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—RAF1—dilated cardiomyopathy	0.000966	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—EGFR—dilated cardiomyopathy	0.000897	0.00147	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—EGFR—dilated cardiomyopathy	0.000858	0.0014	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000851	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000849	0.00139	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—EGFR—dilated cardiomyopathy	0.000845	0.00138	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—EGFR—dilated cardiomyopathy	0.000807	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—EGFR—dilated cardiomyopathy	0.000803	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000803	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—EGFR—dilated cardiomyopathy	0.000799	0.00131	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—EGFR—dilated cardiomyopathy	0.000795	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—dilated cardiomyopathy	0.000783	0.00128	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000763	0.00125	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000755	0.00124	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000755	0.00124	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—EGFR—dilated cardiomyopathy	0.000748	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—EGFR—dilated cardiomyopathy	0.000748	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.000748	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—RAF1—dilated cardiomyopathy	0.000743	0.00122	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—EGFR—dilated cardiomyopathy	0.000741	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—EGFR—dilated cardiomyopathy	0.000734	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—EGFR—dilated cardiomyopathy	0.000731	0.0012	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—NPPA—dilated cardiomyopathy	0.000705	0.00115	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000702	0.00115	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—EGFR—dilated cardiomyopathy	0.000692	0.00113	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—PSEN2—dilated cardiomyopathy	0.000683	0.00112	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.00068	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD36—dilated cardiomyopathy	0.000678	0.00111	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—dilated cardiomyopathy	0.000662	0.00108	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000651	0.00107	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RAC1—dilated cardiomyopathy	0.000639	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000614	0.001	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RAC1—dilated cardiomyopathy	0.000611	0.000999	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000581	0.00095	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000551	0.000901	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—EGFR—dilated cardiomyopathy	0.000509	0.000833	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000478	0.000783	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000473	0.000775	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ITGB1—dilated cardiomyopathy	0.000463	0.000757	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000428	0.0007	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000425	0.000695	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000425	0.000695	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—RAF1—dilated cardiomyopathy	0.000424	0.000693	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000409	0.000669	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000407	0.000665	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—RAF1—dilated cardiomyopathy	0.000405	0.000663	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000395	0.000646	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD36—dilated cardiomyopathy	0.000395	0.000646	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000382	0.000626	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAC1—dilated cardiomyopathy	0.000372	0.000609	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.00036	0.000589	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAC1—dilated cardiomyopathy	0.000344	0.000562	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000338	0.000554	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000327	0.000534	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00031	0.000507	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000306	0.000501	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—EGFR—dilated cardiomyopathy	0.000291	0.000475	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000284	0.000464	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.000279	0.000456	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—EGFR—dilated cardiomyopathy	0.000278	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000266	0.000436	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—RAF1—dilated cardiomyopathy	0.000247	0.000404	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000241	0.000394	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AGT—dilated cardiomyopathy	0.00023	0.000376	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—RAF1—dilated cardiomyopathy	0.000228	0.000373	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000195	0.000318	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—EGFR—dilated cardiomyopathy	0.000169	0.000277	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—RAF1—dilated cardiomyopathy	0.00016	0.000261	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—EGFR—dilated cardiomyopathy	0.000156	0.000256	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000109	0.000179	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	8.32e-05	0.000136	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	8.1e-05	0.000132	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	7.29e-05	0.000119	CbGpPWpGaD
